Red Orbit (Free subscription) | 10 hours ago
NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
PR News Wire (Free subscription) | 9 hours ago
NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The...
Business Wire (Free subscription) | 10 hours ago
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009. Four poster presentations will summarize...
Business Wire (Free subscription) | 10 hours ago
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from more than 200 recent and on-going clinical trials of Celgene products including REVLIMID®, VIDAZA®, THALOMID®, pomalidomide, ACE-011 and Amrubicin at the 51st Annual American Society of Hematology Meeting...
PR News Wire (Free subscription) | yesterday
EMERYVILLE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data...
Medical News Today (Free subscription) | 11/07/2009
Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The approval of ISTODAX was based on objective disease response defined as the proportion of patients with confirmed complete response or partial response....
Medical News Today (Free subscription) | 11/04/2009
The American Society of Hematology (ASH) is honoring two prominent hematologists with ASH Mentor Awards in recognition of the important role they play in the training and career development of hematologists early in their careers. Stuart H. Orkin, MD, and Arthur W. Nienhuis, MD, will receive their awards during the 51st ASH Annual Meeting in New Orleans. Dr.
PR News Wire (Free subscription) | 11/03/2009
WASHINGTON, Nov. 3 /PRNewswire-USNewswire/ -- The American Society of Hematology, the world's largest professional society of blood specialists, welcomes five new officers to its Executive Committee, the governing body of the organization. The officers will begin serving their terms in January 2010.
PR News Wire (Free subscription) | 11/03/2009
WASHINGTON, Nov. 3 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH) is honoring two prominent hematologists with ASH Mentor Awards in recognition of the important role they play in the training and career development of hematologists early in their careers. Stuart H. Orkin, MD, and Arthur W. Nienhuis, MD, will receive their awards during the 51st ASH Annual Meeting in New Orleans....
PR News Wire (Free subscription) | 11/03/2009
TORONTO, Nov. 3 /PRNewswire/ -- Toronto-based Sysmex Canada, Inc. and the Eastern Ontario Regional Lab Association (EORLA) today announced their exclusive five-year Vendor Supply and Capital Equipment Service Agreements. Sysmex Canada will standardize hematology instruments, reagents, training, services and support for Champlain LHIN's hospitals, reference laboratory and allied health facilities within...
Medical News Today (Free subscription) | 11/03/2009
Patients who undergo point-of-care testing at a general practice are as, or more, likely to comply with their medication regimes as patients who undergo testing at a pathology laboratory, according to the results of a study published in the Medical Journal of Australia.
Medical News Today (Free subscription) | 10/28/2009
William Kuo, MD, was the on-call interventional radiologist one Friday night three years ago when he received a call from the intensive care unit at Stanford Hospital & Clinics. He was asked to attend to a 62-year-old woman who had collapsed at home and was rushed to the emergency room with massive blood clots in her lungs. "I get very emotional when I think about what happened," said...
Nature Publishing Group (Free subscription) | 10/28/2009
Maintenance therapy aims to sustain a state of ongoing disease remission. This article discusses the results of randomized trials that suggest that specific subgroups of patients with follicular lymphoma should receive maintenance therapy with rituximab.
Nature Publishing Group (Free subscription) | 10/28/2009
The monoclonal antibody, rituximab, is used to treat lymphomas. This article discusses the results of randomized trials that suggest patients with follicular lymphoma should not receive rituximab maintenance therapy.
Nature Publishing Group (Free subscription) | 10/28/2009
Hematology: Ipilimumab of benefit in unresectable melanoma Nature Reviews Clinical Oncology 6, 618 (2009). doi:10.1038/nrclinonc.2009.155 Author: Mandy Aujla
The last article published by a user on Hematology News :
aarkstore | 09/09/2009
Clinical hematology analyzer analysis is one of the oldest and most important sectors of clinical laboratory analysis. The hematology instrument and reagent market is centered around a group of instruments called hematology analyzers. The term clinical hematology analyzer usually refers to an automated instrument for determining the presence, number and type of cellular elements in easily collected...
Videos